Pharmaceutical giants Actavis and Forest Laboratories have reportedly agreed to forfeit the rights to four generic drugs in order to secure approval for their proposed merger.
Reports say the Federal Trade Commission found that under original terms of the merger, the market would likely face reduced competition when it came to three generic pharmaceuticals, and would likely delay the introduction of a fourth generic.
The settlement, which was accepted by the FTC on Monday, has the companies offering to release those rights to the generic drugs, reports say. The matter is now up for public comment through July 30.
The rights will reportedly be sold to rivals Valeant, Impax and Catalent.
Actavis and Forest first announced their merger plans in February, a deal valued at about $25 billion.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI